| > ABOUT > Best Practice
As an open access journal, Korean Journal of Clinical Oncology (KJCO) will follow the Principles of Transparency and Best Practice in Scholarly Publishing (https://doaj.org/bestpractice) developed by Committee on Publication Ethics (COPE), the Directory of Open Access Journals (DOAJ), the Open Access Scholarly Publishers Association (OASPA), and the World Association of Medical Editors (WAME).
Table of Contents
The URL address of official journal web site is http://kjco.org.
Aims & Scope statement: http://kjco.org/about/index.php
The Korean Journal of Clinical Oncology (Korean J Clin Oncol, KJCO) is an official publication of the Korean Society of Surgical Oncology. KJCO serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. Its scope comprised the followings: gastrointestinal, breast, head and neck cancer and soft tissue tumor including other organs tumors; molecular oncology; cancer prevention; clinical trial for chemotherapy; supportive care and quality of life issues. Its publication types include original articles, reviews, case reports, correspondences, and editorials. The journal is published biannually (June, December) and distributed to members of the Korean Society of Surgical Oncology, medical schools, libraries, and related institutes to pursue the academic advancement in clinical oncology and to promote an active communication between the members and international societies of clinical oncology. Eventually, the Journal aims to cure of cancer and improvement of public health.
Authorship criteria: http://kjco.org/authors/authors.php
Doctors and researchers throughout the world can submit a manuscript if the scope is appropriate for Korean Journal of Clinical Oncology. Manuscripts should be submitted in English.
ISSN Information: pISSN: 1738-8082
2. Name of journal
The official journal title is Korean Journal of Clinical Oncology. Abbreviated title is Korean J Clin Oncol.
3. Peer review process
Type of peer review: Double-blind review
Method of peer review
All submitted manuscripts are screened for duplication through Crosscheck (https://app.ithenticate.com) before review. All contributions (including solicited articles) are critically reviewed by the editorial board members, and/or reviewers. Reviewers' comments are usually returned to authors. The decision of the editor is final. Manuscripts are sent simultaneously to two reviewers for double-blinded peer review. A third reviewer will be assigned if there is a discrepancy between two reviewers. Authors will receive notification of the publication decision, along with copies of the reviews and instruction for revision, if appropriate, within two months after receipt of the submission.
All manuscripts from editors, employees, or members of the editorial board are processed the same way as other unsolicited manuscripts. During the review process, they will not engage in the selection of reviewers and decision process. Editors will not handle their own manuscripts even if they are commissioned ones.
4. Ownership, journal management team, and publishing credentials
The journal is owned by the publisher, the Korean Society of Surgical Oncology (South Korea). https://www.koreansso.org/en/
The management team is as follows:
- Journal Manager: Hyuk Hur, Editor-in-Chief of KJCO, Yonsei University, Korea
- Managers of the Review Process:
Hae Il Jung, Soonchunhyang University, Korea
Jong Hyuk Yun, Soonchunhyang University, Korea
- Ethics Editor:
- Statistics Editor:
- Manuscript Editor: Mi Young Park, Infolumi, Korea
- Website and JATS XML Producer: Min Young Choi, M2PI, Korea
5. Governing body
The governing body is the journal's editorial board.
6. Editorial team and contact information
The Editorial team is available from Editorial Board page at the front part of the journal.
Editor: Hyuk Hur, MD, PhD., Yonsei University, Korea
Korean Society of Surgical Oncology
101-3304 Brownstone Seoul, 464 Cheongpa-ro, Jung-gu, Seoul 04510, Korea
7. Copyright and licensing
Copyright policy: All published papers become the permanent property of the Korean Society of Surgical Oncology. Copyrights of all published materials are owned by the Korean Society of Surgical Oncology and permission must be obtained for any commercial use of materials. Every author should sign the copyright transfer agreement forms.
Licensing information: This is an Open Access journal distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
8. Author fees
There are no author submission fees or other publication-related charges. All cost for the publication process is supported by the Publisher. Korean Journal of Clinical Oncology is a so-called platinum open access journal which does not charge author fees.
9. Process for the identification of and dealing with allegations of research misconduct
When the journal faces suspected cases of research and publication misconduct such as redundant (duplicate) publication, plagiarism, fraudulent or fabricated data, changes in authorship, an undisclosed conflict of interest, ethical problems with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and so on, the resolution process will follow the flowchart provided by the Committee on Publication Ethics (COPE) (http://publicationethics.org/resources/flowcharts). The discussion and decision on the suspected cases are carried out by the Editorial Board.
10. Publication ethics
Journal policies on authorship and contributorship
Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, and/or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Every author should meet all of these four conditions. After the initial submission of a manuscript, any changes whatsoever in authorship (adding author(s), deleting author(s), or re-arranging the order of authors) must be explained by a letter to the editor from the authors concerned. This letter must be signed by all authors of the paper. Copyright assignment must also be completed by every author.
Corresponding author and first author: Korean Journal of Clinical Oncology does not allow multiple corresponding authors for one article. Only one author should correspond with the editorial office and readers for one article. Korean Journal of Clinical Oncology does accept notice of equal contribution for the first author when the study was clearly performed by co-first authors.
Correction of authorship after publication: Korean Journal of Clinical Oncology does not correct authorship after publication unless a mistake has been made by the editorial staff. Authorship may be changed before publication but after submission when an authorship correction is requested by all of the authors involved with the manuscript.
How the journal will handle complaints and appeals
The policy of the journal is primarily aimed at protecting the authors, reviewers, editors, and the publisher of the journal. If not described below, the process of handling complaints and appeals follows the COPE guidelines available from: https://publicationethics.org/appeals.
Who complains or makes an appeal? Submitters, authors, reviewers, and readers may register complaints and appeals in a variety of cases as follows: falsification, fabrication, plagiarism, duplicate publication, authorship dispute, conflict of interest, ethical treatment of animals, informed consent, bias or unfair/inappropriate competitive acts, copyright, stolen data, defamation, and legal problem. If any individuals or institutions want to inform the cases, they can send a letter via the contact page on our website: http://kjco.org/about/contact.php. For the complaints or appeals, concrete data with answers to all factual questions (who, when, where, what, how, why) should be provided.
Who is responsible for resolving and handling complaints and appeals? The Editor, Editorial Board, or Editorial Office is responsible for them. A legal consultant or ethics editor may be able to help with decision making.
What may be the consequence of the remedy? It depends on the type or degree of misconduct. The consequence of resolution will follow the COPE guidelines.
Journal policies on conflicts of interest / competing interests
The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors’ interpretation of the data. Examples of potential conflicts of interest are financial support from or connections to companies, political pressure from interest groups, and academically related issues. In particular, all sources of funding applicable to the study should be explicitly stated.
Journal policies on data sharing and reproducibility;
This journal follows the data sharing policy described in "Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors" (https://doi.org/10.3346/jkms.2017.32.7.1051). As of July 1, 2018 manuscripts submitted to ICMJE journals that report the results of interventional clinical trials must contain a data sharing statement as described below. Clinical trials that begin enrolling participants on or after January 1, 2019 must include a data sharing plan in the trial's registration. The ICMJE's policy regarding trial registration is explained at http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/. If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record.
All of the authors of research articles that deal with interventional clinical trials must submit data sharing plan of example 1 to 4 in Table 1. Based on the degree of sharing plan, authors should deposit their data after de-identification and report the DOI of the data and the registered site.
Table 1. Examples of data sharing statements that fulfill these ICMJE requirements*
|Will individual participant data be available (including data dictionaries)?
|What data in particular will be shared?
|All individual participant data collected during the trial, after deidentification.
|Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
|Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
|What other documents will be available?
|Study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code
|Study protocol, statistical analysis plan, analytic code
|When will data be available (start and end dates)?
|Immediately following publication. No end date.
|Beginning at 3 months and ending at 5 years following the article publication.
|Beginning at 9 months and ending at 36 months following the article publication.
|Anyone who wishes to access the data.
|Researchers who provide a methodologically sound proposal.
|Investigators whose proposed use of the data has been approved by an independent review committee (“learned intermediary”) identified for this purpose.
|For what types of analyses?
|To achieve aims in the approved proposal.
|For individual participant data meta-analysis.
|By what mechanism will data be made available?
|Data are available indefinitely at (link to be included).
|Proposals should be directed to xxx@yyy. To gain access, data requestors will need to sign a data access agreement.
|Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata.
|Data are available for 5 years at a third-party website (link to be included).
|Information regarding submitting proposals and accessing data may be found at (link to be provided).
ICMJE = International Committee of Medical Journal Editors.
*These examples are meant to illustrate a range of, but not all, data sharing options.
Journal's policy on ethical oversight
When the Journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, an ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and other issues, the resolving process will follow the flowchart provided by COPE (http://publicationethics.org/resources/flowcharts). The Editorial Board will discuss the suspected cases and reach a decision. We will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.
Upon discovery of misconduct in research and/or publication ethics, the following actions will be taken: A declaration of manuscript retraction and its reason will be made public via the journal and website and the incident will be shared with the funding agency as applicable, as well as the authors’ institution. A written warning will be issued to authors, who will be banned from submitting manuscripts for a minimum of 3 years. Authors’ membership to the Korean Society of Surgical Oncology will also be cancelled.
Journal's policy on intellectual property
All published papers become the permanent property of the Korean Society of Surgical Oncology. Copyrights of all published materials are owned by the Society.
Journal's options for post-publication discussions and corrections
The post-publication discussion is available through ‘Letter to the Editor’. If any readers have a concern on any articles published, they can submit letters to the editor on the articles. If any errors or mistakes in the article are found, it can be corrected through errata, corrigenda, or retraction.
11. Publishing schedule
Korean Journal of Clinical Oncology is published semiannually on the last day of every June and December. Any supplementary or special issues may be published.
Korean Journal of Clinical Oncology is freely accessible from http://kjco.org according to the Creative Commons License (https://creativecommons.org/licenses/by-nc/4.0/). The copyright, including the right of online transmission, is owned by the Korean Society of Surgical Oncology.
Full text of Korean Journal of Clinical Oncology has been archived in National Library of Korea (http://www.nl.go.kr). According to the deposit policy (self-archiving policy) of Sherpa/Romeo (http://www.sherpa.ac.uk), authors cannot archive pre-print (i.e., pre-refereeing), but they can archive post-print (i.e., final draft post-refereeing). Authors can archive publisher's version/PDF.
14. Revenues sources
Revenue sources of journal are from the support of publisher (Korean Society of Clinical Oncology).
We accept advertising and sponsorship for its printed journal according to the following principles:
- Advertising is separate from content. Advertisers and sponsors have no advance knowledge of our editorial contents, nor do the editors have advance knowledge of advertisers. Content is never altered, added, or deleted to accommodate advertising. Advertisers and sponsors have no input regarding any of our editorial decisions or advertising policies.
- We reserve the right to decline or cancel any advertisement at any time.
- Advertisements for pharmaceutical products must conform to all regulations and policies of the Ministry of Food and Drug Safety, Republic of Korea in every respect.
16. Direct marketing
Journal propagation has been done through the journal web site and distribution of an introduction pamphlet. Invitations to submit a manuscript are usually focused on the presenters at conferences, seminars, or workshops if the topic is related to the journal's aims and scope.